Literature DB >> 16283536

Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science.

Goonaseelan Colin Pillai1, France Mentré, Jean-Louis Steimer.   

Abstract

Few scientific contributions have made significant impact unless there was a champion who had the vision to see the potential for its use in seemingly disparate areas-and who then drove active implementation. In this paper, we present a historical summary of the development of non-linear mixed effects (NLME) modeling up to the more recent extensions of this statistical methodology. The paper places strong emphasis on the pivotal role played by Lewis B. Sheiner (1940-2004), who used this statistical methodology to elucidate solutions to real problems identified in clinical practice and in medical research and on how he drove implementation of the proposed solutions. A succinct overview of the evolution of the NLME modeling methodology is presented as well as ideas on how its expansion helped to provide guidance for a more scientific view of (model-based) drug development that reduces empiricism in favor of critical quantitative thinking and decision making.

Mesh:

Substances:

Year:  2005        PMID: 16283536     DOI: 10.1007/s10928-005-0062-y

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  55 in total

1.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs.

Authors:  S Retout; S Duffull; F Mentré
Journal:  Comput Methods Programs Biomed       Date:  2001-05       Impact factor: 5.428

2.  Use of a pharmacokinetic/pharmacodynamic model to design an optimal dose input profile.

Authors:  K Park; D Verotta; S K Gupta; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1998-08

3.  Do we need full compliance data for population pharmacokinetic analysis?

Authors:  P Girard; L B Sheiner; H Kastrissios; T F Blaschke
Journal:  J Pharmacokinet Biopharm       Date:  1996-06

4.  Computer-assisted digoxin therapy.

Authors:  C C Peck; L B Sheiner; C M Martin; D T Combs; K L Melmon
Journal:  N Engl J Med       Date:  1973-08-30       Impact factor: 91.245

5.  The hierarchical Bayesian approach to population pharmacokinetic modelling.

Authors:  A Smith; J Wakefield
Journal:  Int J Biomed Comput       Date:  1994-06

6.  Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1983-06

Review 7.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

Review 8.  Pharmacokinetic and pharmacodynamic modeling in vivo.

Authors:  N H Holford; L B Sheiner
Journal:  Crit Rev Bioeng       Date:  1981

9.  Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-10

10.  A Markov mixed effect regression model for drug compliance.

Authors:  P Girard; T F Blaschke; H Kastrissios; L B Sheiner
Journal:  Stat Med       Date:  1998-10-30       Impact factor: 2.373

View more
  28 in total

1.  Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models.

Authors:  Elodie L Plan; Alan Maloney; France Mentré; Mats O Karlsson; Julie Bertrand
Journal:  AAPS J       Date:  2012-04-14       Impact factor: 4.009

Review 2.  Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.

Authors:  Stephen B Duffull; Daniel F B Wright; Helen R Winter
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

Review 3.  A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.

Authors:  Robert J Bauer; Serge Guzy; Chee Ng
Journal:  AAPS J       Date:  2007-03-02       Impact factor: 4.009

Review 4.  Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.

Authors:  C Dartois; K Brendel; E Comets; C M Laffont; C Laveille; B Tranchand; F Mentré; A Lemenuel-Diot; P Girard
Journal:  Br J Clin Pharmacol       Date:  2007-08-15       Impact factor: 4.335

5.  Prediction of shrinkage of individual parameters using the bayesian information matrix in non-linear mixed effect models with evaluation in pharmacokinetics.

Authors:  François Pierre Combes; Sylvie Retout; Nicolas Frey; France Mentré
Journal:  Pharm Res       Date:  2013-06-07       Impact factor: 4.200

6.  Pharmacokinetic similarity of biologics: analysis using nonlinear mixed-effects modeling.

Authors:  A Dubois; S Gsteiger; S Balser; E Pigeolet; J L Steimer; G Pillai; F Mentré
Journal:  Clin Pharmacol Ther       Date:  2011-12-28       Impact factor: 6.875

7.  Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.

Authors:  Julie Bertrand; Emmanuelle Comets; Céline M Laffont; Marylore Chenel; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-06-27       Impact factor: 2.745

8.  A survey of the way pharmacokinetics are reported in published phase I clinical trials, with an emphasis on oncology.

Authors:  Emmanuelle Comets; Sarah Zohar
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  Explicit reformulations of the Lambert W-omega function for calculations of the solutions to one-compartment pharmacokinetic models with Michaelis-Menten elimination kinetics.

Authors:  Marko Goličnik
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-05-01       Impact factor: 2.441

Review 10.  Fundamentals of Population Pharmacokinetic Modelling : Modelling and Software.

Authors:  Tony K L Kiang; Catherine M T Sherwin; Michael G Spigarelli; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2012-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.